Tag: Cancer: Prostate
BMD Testing Rates Low in Men Initiating ADT for Prostate Cancer
Odds of BMD testing up with history of osteoporosis, rheumatoid arthritis, bisphosphonate use
Adjuvant Radiotherapy No Better for Localized Prostate Cancer
Event-free survival not improved with use of adjuvant versus early salvage radiotherapy
Ultrasound Ablation Offers Option for Some With Prostate Cancer
Bilateral prostate cancer at diagnosis was sole predictor of Grade Group 2 or greater recurrence
Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer
Risk for death significantly lower versus placebo in nonmetastatic, castration-resistant prostate cancer
Factors Clarify Racial Disparity in Prostate Cancer Survival
Education, median household income, and insurance status contribute most to racial disparity in the U.S.
Delayed Radiotherapy Not Tied to Worse Survival in Prostate Cancer
Initiation of RT up to six months after androgen deprivation therapy not tied to worse overall survival
Guidance Issued for Genetic Testing in Prostate Cancer
Germline testing advised for metastatic disease, family history suggestive of hereditary disease
Delayed Radiotherapy Not Tied to Worse Survival in Prostate Cancer
Initiation of RT up to six months after androgen deprivation therapy not tied to worse overall survival
Prostate Cancer Trial Participants Overwhelmingly White
Since 1990, proportion of white participants in prostate cancer clinical trials has remained >80 percent
ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer
And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer
